{
  "context": {
    "rules": [
      "Rule1: If material D37 has approval from the research department, then it is safe for human use.",
      "Rule2: Material D37 has completed clinical trial or it has published results.",
      "Rule3: Whenever material D37 has published results, it is approved for distribution.",
      "Rule4: If material D37 has a patent pending, then it is not the case that it has a patent granted.",
      "Rule5: Either material D37 has a patent pending, or if it has completed clinical trial then it is authorized for production.",
      "Rule6: If application M42 is under patent office review, then whenever material D37 has a patent pending, it has a patent granted.",
      "Rule7: Manufacturing of material D37 is active or production is not halted.",
      "Rule8: Provided that material D37 is regulatory compliant, manufacturing is not active.",
      "Rule9: Whenever material D37 meets GMP standards, it is regulatory compliant.",
      "Rule10: If material D37 has approval from the quality department, then it is safe for human use.",
      "Rule11: Either material D37 failed the quality audit, or if it passed FDA inspection then it meets GMP standards.",
      "Rule12: Provided that material D37 passed quality assurance, if it is not safe for human use then it is not under market recall.",
      "Rule13: Under the condition that the batch of material D37 is certified, if it is not safe for human use then it is not under market recall.",
      "Rule14: If material D37 passed stability testing, then it passed quality assurance.",
      "Rule15: Either material D37 passed stability testing or it passed accelerated aging test.",
      "Rule16: If technical review of material D37 is complete, then whenever it is not the case that accelerated aging pass implies batch certification, there is a formulation issue.",
      "Rule17: If material D37 has a sales license granted, then under the condition of marketing clearance, provided packaging is certified, labeling is approved.",
      "Rule18: If material D37 has a distribution permit, then provided it has marketing clearance, whenever packaging is certified, labeling is approved.",
      "Rule19: Provided that inspection findings for material D37 are resolved, it does not have a regulatory violation.",
      "Rule20: Inspection findings for material D37 are resolved or corrective actions are completed.",
      "Rule21: If corrective actions for material D37 are completed, then it is not the case that it has a regulatory violation.",
      "Rule22: Validation documentation for material D37 is approved or it passed quality system audit.",
      "Rule23: Whenever material D37 passed toxicity test, it does not have a contamination risk.",
      "Rule24: Material D37 passed toxicity test or it is approved for trial.",
      "Rule25: If material D37 passed quality system audit, then under the condition that process validation is complete, equipment is qualified.",
      "Rule26: Either manufacturing of material D37 is suspended, or if it is not the case that validation documentation approval implies process validation completeness leads to equipment qualification, and this not leading to validation protocol requirement implies requalification is needed.",
      "Rule27: Provided that sterile processing of material D37 is verified, it does not have a contamination risk.",
      "Rule28: Either microbial contamination is detected in material D37, or if it passed endotoxin testing then sterile processing is verified.",
      "Rule29: If material D37 passed environmental monitoring, then a contamination event occurred.",
      "Rule30: Material D37 passed environmental monitoring or if microbial contamination is detected then the batch is rejected.",
      "Rule31: Under the condition that material D37 is approved for trial, it passed endotoxin testing.",
      "Rule32: If material D37 passed air quality test, then the cleanroom is certified.",
      "Rule33: Material D37 passed air quality test or surface sterility is confirmed.",
      "Rule34: Provided that surface sterility of material D37 is confirmed, if it passed environmental monitoring then no contamination event occurred.",
      "Rule35: If material D37 has research committee approval, then it has approval from the research department.",
      "Rule36: Material D37 has research committee approval or it has safety board approval.",
      "Rule37: If preclinical studies for material D37 are complete, then provided it has safety board approval, it has approval from the quality department.",
      "Rule38: Preclinical studies for material D37 are complete or animal testing was successful.",
      "Rule39: Provided that animal testing for material D37 was successful, if it has safety board approval then it has approval from the quality department.",
      "Rule40: Under the condition that post-market surveillance is active for material D37, either a follow-up study is required or a stability concern implies a formulation issue.",
      "Rule41: Whenever material D37 meets purity standard, it does not have a contamination risk.",
      "Rule42: The cold chain is maintained for material D37 or a validated shipping procedure exists.",
      "Rule43: Under the condition that a validated shipping procedure exists for material D37, if it experienced a temperature excursion then there is a storage condition problem.",
      "Rule44: If logistics for material D37 are qualified, then provided the cold chain is maintained, whenever a temperature excursion occurs, a storage condition problem follows.",
      "Rule45: Whenever transport conditions are met for material D37, if it passed accelerated aging test then the batch is certified.",
      "Rule46: Provided that the carrier for material D37 is certified, transport conditions are met.",
      "Rule47: Either the carrier for material D37 is certified or shipping validation is complete.",
      "Rule48: Material D37 requires retesting or if it is approved for trial then it meets purity standard.",
      "Rule49: Provided that patient safety monitoring is active for material D37, if it is not the case that not safe for human use implies no market recall, then an adverse event report is filed.",
      "Rule50: If pharmacovigilance is active for material D37, then under the condition that not safe for human use does not lead to no market recall, an adverse event report is filed.",
      "Rule51: Whenever the benefit-risk assessment is favorable for material D37, the risk management plan is approved.",
      "Rule52: The benefit-risk assessment is favorable for material D37 or a safety profile is established.",
      "Rule53: Provided that a safety profile is established for material D37, if neither patient safety monitoring nor pharmacovigilance is active, then no safety alert is issued.",
      "Rule54: If material D37 is authorized for production, then it is safe for human use.",
      "Rule55: Under the condition that material D37 is approved for distribution, it is safe for human use.",
      "Rule56: If it is not the case that material D37 has approval from the research department or the quality department, then it has a contamination risk.",
      "Rule57: Provided that it is not the case that accelerated aging pass leads to batch certification, there is a stability concern.",
      "Rule58: If accelerated aging pass does not result in batch certification, then there is a shelf-life issue.",
      "Rule59: If regulatory approval does not lead to safety for human use, then packaging is certified.",
      "Rule60: Provided that regulatory approval does not guarantee safety for human use, labeling is not approved.",
      "Rule61: Whenever it is not the case that material D37 has a sales license granted or a distribution permit, there is a regulatory violation.",
      "Rule62: Under the condition that approval for trial does not lead to meeting purity standard, process validation is complete.",
      "Rule63: If a shelf-life issue does not result in a formulation issue, then a temperature excursion occurs.",
      "Rule64: Whenever shipping validation completeness does not lead to transport conditions being met, transport deviations occur.",
      "Rule65: If it is not the case that patient safety monitoring or pharmacovigilance is active, then a safety alert is issued.",
      "Rule66: If material D37 is not safe for human use, then production is halted.",
      "Rule67: Whenever material D37 is not safe for human use, it is under market recall."
    ],
    "facts": [
      "Fact1: Application M42 is under patent office review.",
      "Fact2: Material D37 passed FDA inspection.",
      "Fact3: Technical review of material D37 is complete.",
      "Fact4: Material D37 has regulatory approval.",
      "Fact5: Material D37 has marketing clearance.",
      "Fact6: Post-market surveillance is active for material D37.",
      "Fact7: Logistics for material D37 are qualified.",
      "Fact8: Material D37 did not fail the quality audit.",
      "Fact9: Material D37 does not have a formulation issue.",
      "Fact10: Equipment for material D37 is not qualified.",
      "Fact11: A validation protocol is not required for material D37.",
      "Fact12: Requalification is not needed for material D37.",
      "Fact13: Manufacturing of material D37 is not suspended.",
      "Fact14: The batch of material D37 is not rejected.",
      "Fact15: The cleanroom for material D37 is not certified.",
      "Fact16: A follow-up study is not required for material D37.",
      "Fact17: Material D37 does not have a storage condition problem.",
      "Fact18: Transport deviations did not occur for material D37.",
      "Fact19: Material D37 does not require retesting.",
      "Fact20: An adverse event report is not filed for material D37.",
      "Fact21: The risk management plan is not approved for material D37."
    ]
  },
  "question": "Material D37 is safe for human use."
}